The suppression of puerperal lactation with bromocryptine. 1977

M P Willmott, and E M Colhoun, and A E Bolton

The therapeutic value of 2-Br-alpha-ergocryptine for the suppression of puerperal lactation was studied in 30 normal women; 16 received the drug, 14 were controls. In six women plasma levels of FSH, oestradiol and alpha-lactalbulmin were measured in labour and in the early puerperium. Brom-ergocryptine was found effectively to suppress milk production and alleviate breast pain and congestion, with no side effects and minimum rebound lactation. The inverse relationship between prolactin and FSH levels reported elsewhere in non-pregnant women did not appear to occur in the early postpartum period. Although there was a significant rise in alpha-lactalbumin levels in labour and the puerperium over non-pregnant levels, there was no difference between lactating and non-lactating women.

UI MeSH Term Description Entries
D007768 Lactalbumin A major protein fraction of milk obtained from the WHEY. alpha-Lactalbumin,alpha-Lactalbumin A,alpha-Lactalbumin B,alpha-Lactalbumin C,alpha Lactalbumin,alpha Lactalbumin A,alpha Lactalbumin B,alpha Lactalbumin C
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females

Related Publications

M P Willmott, and E M Colhoun, and A E Bolton
July 1972, British medical journal,
M P Willmott, and E M Colhoun, and A E Bolton
April 1977, Irish medical journal,
M P Willmott, and E M Colhoun, and A E Bolton
October 1964, GP,
M P Willmott, and E M Colhoun, and A E Bolton
April 1986, American journal of obstetrics and gynecology,
M P Willmott, and E M Colhoun, and A E Bolton
January 1979, Acta obstetricia et gynecologica Scandinavica,
M P Willmott, and E M Colhoun, and A E Bolton
January 1978, Obstetrics and gynecology,
M P Willmott, and E M Colhoun, and A E Bolton
August 1967, Lancet (London, England),
M P Willmott, and E M Colhoun, and A E Bolton
August 1976, Ugeskrift for laeger,
M P Willmott, and E M Colhoun, and A E Bolton
January 1983, Nihon Sanka Fujinka Gakkai zasshi,
M P Willmott, and E M Colhoun, and A E Bolton
July 1975, American journal of obstetrics and gynecology,
Copied contents to your clipboard!